MARKET

PODD

PODD

Insulet
NASDAQ

Real-time Quotes | Nasdaq Last Sale

226.08
+1.51
+0.67%
Opening 13:38 09/22 EDT
OPEN
224.87
PREV CLOSE
224.57
HIGH
226.27
LOW
220.20
VOLUME
121.71K
TURNOVER
--
52 WEEK HIGH
233.99
52 WEEK LOW
121.00
MARKET CAP
14.84B
P/E (TTM)
815.00
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Insulet's Omnipod DASH Shines, New Omnipod Uptake Slows Down
Insulet (PODD) adds significant capacity in preparation of the Omnipod 5 launch in 2021.
Zacks · 1d ago
Insulet Expands its Offering of Omnipod DASH® Insulin Management System
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it is commercially launching its Omnipod DASH® Insulin Management System (Omnipod DASH System) in additional
Business Wire · 1d ago
Insulet expands DASH launch
Insulet (PODD) announces that it has launched its Omnipod DASH System in Sweden, Finland, Norway and Denmark, and will add France, Belgium, Germany, Austria, Switzerland and Israel in the coming
Seekingalpha · 1d ago
Hedge Funds Never Been This Bullish On Insulet Corporation (PODD)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find articles about an
Insider Monkey · 09/07 21:14
Why Is Insulet (PODD) Down 7.1% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/05 16:31
Insulet Shows Market Leadership With Jump To 82 RS Rating
Investor's Business Daily · 09/01 19:20
Insulet (PODD) Banks on Omnipod Uptake Amid Coronavirus Woes
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Zacks · 08/25 15:44
Insulet to Present at Upcoming Investor Conferences
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at two virtual investor conferences:
Business Wire · 08/24 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PODD stock price target is 241.41 with a high estimate of 260.00 and a low estimate of 210.00.
EPS
Institutional Holdings
Institutions: 554
Institutional Holdings: 74.34M
% Owned: 113.23%
Shares Outstanding: 65.65M
TypeInstitutionsShares
Increased
176
4.38M
New
106
1.03M
Decreased
120
4.65M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.78%
Healthcare Equipment & Supplies
-0.61%
Key Executives
Chairman/Independent Director
Timothy Scannell
Chairman/Independent Director
timothy Scannell
President/Chief Executive Officer/Director
Shacey Petrovic
Chief Financial Officer/Executive Vice President/Treasurer
Wayde McMillan
Chief Operating Officer/Executive Vice President
Charles Alpuche
Executive Vice President
Bret Christensen
Senior Vice President/General Counsel/Secretary
John Kapples
Senior Vice President
Eric Benjamin
Senior Vice President
Michael Spears
Independent Director
Sally Crawford
Independent Director
John Fallon
Independent Director
James Hollingshead
Independent Director
Jessica Hopfield
Independent Director
David Lemoine
Independent Director
Michael Minogue
Independent Director
Corinne Nevinny
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average PODD stock price target is 241.41 with a high estimate of 260.00 and a low estimate of 210.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PODD
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Insulet Corporation stock information, including NASDAQ:PODD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PODD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PODD stock methods without spending real money on the virtual paper trading platform.